2. Signaling Pathways
  3. GPCR/G Protein
  4. GHSR
  5. GHSR Isoform
  6. GHSR Agonist

GHSR Agonist

GHSR Agonists (27):

Cat. No. Product Name Effect Purity
  • HY-14734
    Anamorelin
    		Agonist 99.94%
    Anamorelin (RC-1291) is a potent ghrelin receptor agonist with EC50 value of 0.74 nM in the FLIPR assay.
  • HY-50844
    Ibutamoren Mesylate
    		Agonist 99.86%
    Ibutamoren Mesylate (MK-677) is a potent, non-peptide Growth hormone secretagogue receptor (GHSR) agonist. Ibutamoren Mesylate is an orally active growth hormone (GH) secretagogue.
  • HY-103007
    TC-G-1008
    		Agonist 99.61%
    TC-G-1008 (GPR39-C3) is a potent and orally available GPR39 agonist with EC50 values of 0.4 and 0.8 nM for rat and human receptors respectively.
  • HY-14734A
    Anamorelin hydrochloride
    		Agonist 99.97%
    Anamorelin (RC-1291) hydrochloride is a potent ghrelin receptor agonist with EC50 value of 0.74 nM in the FLIPR assay.
  • HY-10957A
    L-692429 hydrochloride
    		Agonist
    L-692429 (MK-0751) hydrochloride is a benzolactam derivative and a nonpeptidyl growth hormone secretagogue (GHS) agonist. L-692429 hydrochloride binds to G protein-coupled receptor with a Ki of 63 nM.
  • HY-108699
    TM-N1324
    		Agonist 99.91%
    TM-N1324 is an agonist of G-Protein-Coupled Receptor 39 (GPR39) with EC50s of 9 nM/5 nM in the presence of Zn2+, and 280 nM/180 nM in the absence of Zn2+ for human/murine GPR39.
  • HY-19884B
    Relamorelin TFA
    		Agonist 99.89%
    Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research.
  • HY-P3304
    MR 409
    		Agonist 99.51%
    MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer.
  • HY-10957
    L-692429
    		Agonist 99.90%
    L-692429 (MK-0751) is a benzolactam derivative and a nonpeptidyl growth hormone secretagogue (GHS) agonist. L-692429 binds to G protein-coupled receptor with a Ki of 63 nM.
  • HY-15243
    Capromorelin Tartrate
    		Agonist 98.19%
    Capromorelin Tartrate is an orally active, potent growth hormone secretagogue receptor (GHSR) agonist, with Ki of 7 nM for hGHS-R1a.
  • HY-50760
    L-692585
    		Agonist 99.32%
    L-692585 is a potent and nonpeptidyl growth hormone secretagogue receptor (GHS-R1a) agonist, with a Ki of 0.8 nM. L-692585 acts directly on somatotropes causing GH release.
  • HY-14903
    Ulimorelin
    		Agonist
    Ulimorelin (TZP-101) is a ghrelin receptor (GRLN) agonist with an EC50 of 29 nM and a Ki of 16 nM. Ulimorelin is a prokinetic agent and causes vasorelaxation through competitive antagonist action at α1-adrenoceptors. Ulimorelin stimulates intestinal motility and is used for malnutrition.
  • HY-19884
    Relamorelin
    		Agonist
    Relamorelin (RM-131), a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin is centrally penetrant. Relamorelin increases growth hormone levels and accelerates gastric emptying. Relamorelin has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research.
  • HY-19884A
    Relamorelin acetate
    		Agonist
    Relamorelin (RM-131) acetate, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin acetate is centrally penetrant. Relamorelin acetate increases growth hormone levels and accelerates gastric emptying. Relamorelin acetate has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research.
  • HY-10199A
    Ibutamoren
    		Agonist
    Ibutamoren (MK-677) is an orally active growth hormone secretagogue receptor (GHSR) agonist and a nonpeptide growth hormone secretagogue. Ibutamoren can be used for metabolic research.
  • HY-145364
    Ghrelin receptor full agonist-2
    		Agonist
    Ghrelin receptor full agonist-2 (compound 12j) is a highly potent Ghrelin receptor full agonist.
  • HY-115272
    GSK894490A
    		Agonist
    GSK894490A is a non-peptide ghrelin receptor agonist.
  • HY-14495A
    BMS-604992 free base
    		Agonist
    BMS-604992 (EX-1314) free base is a selective, orally active small-molecule growth hormone secretagogue receptor (GHSR) agonist. BMS-604992 free base demonstrates high-affinity binding (ki=2.3 nM) and potent functional activity (EC50=0.4 nM). BMS-604992 free base can stimulate food intake in rodents.
  • HY-153095
    PF-6870961
    		Agonist
    PF-6870961 is an inverse agonist of GHSR1a with Ki values of 73.6 nM (human GHSR), 239 nM (rat GHSR), and 217 nM (dog GHSR), respectively. PF-6870961 inhibits the constitutive GHSR1a-induced IP accumulation with an IC50 value of 300 nM. PF-6870961 also inhibits constitutive GHSR1a β-arrestin mobilization with an IC50 value of 1.10 nM.
  • HY-14820A
    Macimorelin acetate
    		Agonist 98.96%
    Macimorelin (EP-1572) acetate, a GH secretagogue, is an orally active GHSR agonist. Macimorelin acetate stimulates GH release. Macimorelin acetate can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS).